 VANCOUVER, Washington--BUSINESS WIRE--CytoDyn Inc. OTCQB: CYDY CytoDyn or the Company, a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Brazils regulatory authority ANVISA Agência Nacional de Vigilância Sanitária has approved the previously submitted clinical trial protocol to commence patient enrollment in its CD17 trial for severe COVID-19 patients. The Academic Research Organ 